🏡 HomeMenuNewsA - Z

Metachromatic Leukodystrophy Information

  • Date : 2009-04-04
  • Sally Rider
  • Synopsis : Metachromatic leukodystrophy MLD is a hereditary degenerative disease transmitted as an autosomal recessive due to sulfatase a deficiency with excess accumulation of sulfated lipids responsible for metachromasia in various tissues.

Main Document

Metachromatic leukodystrophy (MLD) is a hereditary degenerative disease transmitted as an autosomal recessive, due to sulfatase a deficiency, with excess accumulation of sulfated lipids responsible for metachromasia in various tissues.

Metachromatic leukodystrophy (MLD) is a hereditary degenerative disease transmitted as an autosomal recessive, due to sulfatase a deficiency, with excess accumulation of sulfated lipids responsible for metachromasia in various tissues.

Alternate Names: Arylsulfatase A Deficiency (ARSA), Cerebroside Sulfatase Deficiency, Metachromatic Form of Diffuse Cerebral Sclerosis, Metachromatic Leukoencephalopathy, Scholz-Bielchowsky-Henneberg Diffuse Cerebral Sclerosis, Scholz-Greenfield Disease, Sulphatide Lipidosis, Sulphatidosis, Van Bogaert-Nijssen Disease

MLD impairs the growth or development of the myelin sheath, the fatty covering that acts as an insulator around nerve fibers.

Late infantile form, which is the most common MLD, usually begins in the second year of life (ranges 1-3 years). After normal early development, the infant displays irritability and an unstable walk. Developmental milestones, such as language development, are not met, and muscle wasting eventually gives way to spastic movements, then profound weakness. Seizures usually occur, followed by paralysis and dementia. Children may become comatose.

Diagnosis of MLD includes MRI to identify lesions and atrophy in the white matter of the brain that is characteristic of MLD. Urine tests usually show elevated sulfatide levels. Some psychiatric disorders coupled with difficulty walking or muscle wasting suggests the possibility of MLD. Blood testing can show a reduced activity of the ARSA enzyme.

Deficiency of the ARSA enzyme alone is not proof of MLD, because a substantial ARSA deficiency without any symptoms or clinical consequences is frequent in the general population. During diagnosis and genetic counseling, these harmless ARSA enzyme deficiencies must be distinguished from those causing MLD. The only diagnostic test that solves this problem and is definitive for MLD diagnosis is analysis of the genetic mutation.

No effective treatment is available to reverse the course of MLD. Drug therapy is part of supportive care for symptoms such as behavioral disturbances, feeding difficulties, seizures, and constipation. Bone marrow transplantation has been tried and there is evidence that this treatment might slow the progression of the disease. In infants, during a symptom-free phase of the late infantile form, neuro-cognitive function may be stabilized, but the symptoms of motor function loss progress.

The prognosis for MLD is poor. In young children with MLD late infantile form, progressive loss of motor and cognitive functions is rapid. Death usually results within five years after the onset of clinical symptoms.



• Important Disclaimer: Information provided on Disabled World is for general informational and educational purposes only, it is not offered as and does not constitute medical advice. In no way are any of the materials presented meant to be a substitute for professional medical care or attention by a qualified practitioner, nor should they be construed as such. Any third party offering or advertising on this website does not constitute an endorsement by Disabled World. Please report outdated or inaccurate information.
© 2004 - 2018 Disabled World™